NASDAQ:ONCS', 'OncoSec Medical Incorporated', 'http://kldaily.com/kl-logo.png');

OncoSec Medical Incorporated (ONCS) Analysts See $-0.23 EPS

December 8, 2017 - By Michael Collier

 OncoSec Medical Incorporated (ONCS) Analysts See $ 0.23 EPS

Analysts expect OncoSec Medical Incorporated (NASDAQ:ONCS) to report $-0.23 EPS on December, 14.They anticipate $0.06 EPS change or 20.69 % from last quarter’s $-0.29 EPS. After having $-0.28 EPS previously, OncoSec Medical Incorporated’s analysts see -17.86 % EPS growth. The stock decreased 6.04% or $0.11 during the last trading session, reaching $1.71. About 1.56 million shares traded. OncoSec Medical Incorporated (NASDAQ:ONCS) has declined 34.57% since December 8, 2016 and is downtrending. It has underperformed by 51.27% the S&P500.

OncoSec Medical Incorporated (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 8 analyst reports since March 9, 2016 according to SRatingsIntel. The company was maintained on Tuesday, June 13 by Noble Financial. The firm earned “Buy” rating on Thursday, June 8 by Maxim Group. Rodman & Renshaw reinitiated OncoSec Medical Incorporated (NASDAQ:ONCS) rating on Thursday, July 21. Rodman & Renshaw has “Buy” rating and $6 target. The firm has “Buy” rating given on Wednesday, March 9 by H.C. Wainwright. Maxim Group maintained OncoSec Medical Incorporated (NASDAQ:ONCS) on Friday, June 2 with “Buy” rating. The stock of OncoSec Medical Incorporated (NASDAQ:ONCS) has “Buy” rating given on Friday, June 2 by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, November 9 report. H.C. Wainwright maintained OncoSec Medical Incorporated (NASDAQ:ONCS) rating on Monday, June 12. H.C. Wainwright has “Buy” rating and $600 target.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. The company has market cap of $60.56 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. It currently has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

More recent OncoSec Medical Incorporated (NASDAQ:ONCS) news were published by: Prnewswire.com which released: “OncoSec Receives $9.3 Million Warrant Exercise” on November 13, 2017. Also Prnewswire.com published the news titled: “OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief …” on December 05, 2017. Streetinsider.com‘s news article titled: “Oncosec Medical (ONCS) Enters Warrant Exercise Agreement” with publication date: November 13, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.